194 related articles for article (PubMed ID: 19730774)
1. Long-term survivors of glioblastoma: clinical features and molecular analysis.
Sonoda Y; Kumabe T; Watanabe M; Nakazato Y; Inoue T; Kanamori M; Tominaga T
Acta Neurochir (Wien); 2009 Nov; 151(11):1349-58. PubMed ID: 19730774
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival with glioblastoma multiforme.
Krex D; Klink B; Hartmann C; von Deimling A; Pietsch T; Simon M; Sabel M; Steinbach JP; Heese O; Reifenberger G; Weller M; Schackert G;
Brain; 2007 Oct; 130(Pt 10):2596-606. PubMed ID: 17785346
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
5. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
6. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
7. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
8. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
10. [Glioblastomas: clinical study and search for prognostic factors].
Mineo JF; Quintin-Roue I; Lucas B; Buburusan V; Besson G
Neurochirurgie; 2002 Dec; 48(6):500-9. PubMed ID: 12595806
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
12. Is older age associated with a worse prognosis due to different patterns of care? A long-term study of 1346 patients with glioblastomas or brain metastases.
Lutterbach J; Bartelt S; Momm F; Becker G; Frommhold H; Ostertag C
Cancer; 2005 Mar; 103(6):1234-44. PubMed ID: 15666327
[TBL] [Abstract][Full Text] [Related]
13. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience.
Schlosser S; Wagner S; Mühlisch J; Hasselblatt M; Gerss J; Wolff JE; Frühwald MC
Pediatr Blood Cancer; 2010 Feb; 54(2):228-37. PubMed ID: 19856394
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
17. A review of the treatment and survival rates of 138 patients with glioblastoma multiforme.
Jubelirer SJ
W V Med J; 1996; 92(4):186-90. PubMed ID: 8772403
[TBL] [Abstract][Full Text] [Related]
18. Survival trends in elderly patients with glioblastoma multiforme: resective surgery, radiation, and chemotherapy.
Patwardhan RV; Shorter C; Willis BK; Reddy P; Smith D; Caldito GC; Nanda A
Surg Neurol; 2004 Sep; 62(3):207-13; discussion 214-5. PubMed ID: 15336860
[TBL] [Abstract][Full Text] [Related]
19. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
McLendon RE; Halperin EC
Cancer; 2003 Oct; 98(8):1745-8. PubMed ID: 14534892
[TBL] [Abstract][Full Text] [Related]
20. [Strategy for studying gene methylation: the example of MGMT].
Fina F; Nanni-Metellus I; Courdy C; Figarella-Branger D; Martin PM; Ouafik L
Ann Pathol; 2009 Nov; 29 Spec No 1():S37-9. PubMed ID: 19887248
[No Abstract] [Full Text] [Related]
[Next] [New Search]